{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:15Z","timestamp":1792508235731,"version":"4.5.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The application of circulating tumor DNA (ctDNA) has advanced in the treatment of multiple cancer types, including urothelial cancer (UC). While ctDNA currently plays a limited role in non-muscle-invasive bladder cancer (NMIBC), its relevance is expanding in muscle-invasive bladder cancer (MIBC), as evidenced by recent positive results from the IMvigor011 trial. This study demonstrated that a ctDNA-guided approach to adjuvant atezolizumab therapy enhances disease-free survival. Furthermore, ctDNA is well-established as a tool for monitoring treatment response and assessing minimal residual disease (MRD) in metastatic urothelial cancer (mUC). This narrative review explores the current data on the clinical utility of ctDNA in various disease states within UC to help guide clinicians in the appropriate setting and application of ctDNA based on retrospective, current, and emerging data.<\/jats:p>","DOI":"10.3389\/fonc.2026.1767712","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:28:08Z","timestamp":1775795288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers"],"prefix":"10.3389","volume":"16","author":[{"given":"Jeanny B.","family":"Aragon-Ching","sequence":"first","affiliation":[{"name":"Genitourinary (GU) Medical Oncology, Inova Schar Cancer Institute","place":["Fairfax, VA, United States"]},{"name":"Department of Medical Education, University of Virginia","place":["Charlottesville, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine","place":["Tokyo, Japan"]},{"name":"Department of Urology, The Jikei University West Medical Center","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Yajima","sequence":"additional","affiliation":[{"name":"Department of Urology, National Cancer Center Hospital East","place":["Kashiwa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/BLC-170140","article-title":"Liquid biopsy-analysis of circulating tumor DNA (ctDNA) in bladder cancer","volume":"4","author":"Todenhofer","year":"2018","journal-title":"Bladder Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70215","article-title":"Current status and future perspectives of molecular residual disease testing in genitourinary cancers","volume":"32","author":"Kato","year":"2025","journal-title":"Int J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-471912","article-title":"Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma","volume":"45","author":"Bellmunt","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2025.5724","article-title":"Unleashing the power of urine-based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (review)","volume":"66","author":"Wan","year":"2025","journal-title":"Int J Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-8981(01)00665-9","article-title":"About the possible origin and mechanism of circulating DNA apoptosis and active DNA release","volume":"313","author":"Stroun","year":"2001","journal-title":"Clin Chim Acta"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121908","article-title":"Circulating tumor DNA in muscle-invasive bladder cancer: implications for prognosis and treatment personalization","volume":"17","author":"Katsimperis","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2020.01.005","article-title":"Liquid biopsies using circulating tumor DNA in non-small cell lung cancer","volume":"30","author":"Pellini","year":"2020","journal-title":"Thorac Surg Clin"},{"key":"B14","doi-asserted-by":"publisher","first-page":"19606","DOI":"10.1038\/s41598-019-55872-7","article-title":"Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform","volume":"9","author":"Dueck","year":"2019","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10147-024-02493-4","article-title":"Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay","volume":"29","author":"Hashimoto","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104124","article-title":"Development of a technique for diagnosis and screening of superficial bladder cancer by cell-pellet DNA from urine sample","volume":"105","author":"Seok","year":"2025","journal-title":"Lab Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtroder","year":"2016","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","article-title":"Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial","volume":"23","author":"Wu","year":"2024","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e16588","article-title":"UriFind assay and association with whole course management of urothelial carcinoma in a large multicentric, prospective China cohort","volume":"41","author":"Chen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512489","article-title":"Bladder Epicheck test: a novel tool to support urothelial carcinoma diagnosis in urine samples","volume":"24","author":"Fiorentino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206633","article-title":"Methylation study of the Paris system for reporting urinary (TPS) categories","volume":"74","author":"Pierconti","year":"2021","journal-title":"J Clin Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40364-023-00488-3","article-title":"Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression","volume":"11","author":"Shi","year":"2023","journal-title":"biomark Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2022.2028805","article-title":"CD274 (PD-L1) methylation is an independent predictor for bladder cancer patients' survival","volume":"40","author":"Xu","year":"2022","journal-title":"Cancer Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16580","article-title":"Comparison of clinical outcomes of bladder preservation and surgery in a real-world study of patients with muscle invasive urothelial carcinoma using urine and plasma based MRD (minimal residual disease) assays","volume":"42","author":"Au","year":"2024","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B29","article-title":"Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study","volume":"33","author":"Hauser","year":"2013","journal-title":"Anticancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657483","article-title":"Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.05.019","article-title":"Real-world experience with a commercial circulating tumor DNA assay in non-muscle-invasive bladder cancer","volume":"8","author":"Wang","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","volume":"7","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101763","article-title":"Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials","volume":"37","author":"Nawaf","year":"2023","journal-title":"Transl Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","author":"Sfakianos","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16556","article-title":"Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes","volume":"135","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911732","article-title":"Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"66 e9","DOI":"10.1016\/j.urolonc.2024.08.006","article-title":"The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: a contemporary analysis","volume":"43","author":"Ben-David","year":"2025","journal-title":"Urol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316578","article-title":"Tumor-agnostic circulating tumor DNA testing for monitoring muscle-invasive bladder cancer","volume":"24","author":"Carrasco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2026.102512","article-title":"Tumor-informed circulating tumor DNA (ctDNA) in locally advanced and metastatic urothelial carcinoma: a retrospective single-center cohort","volume":"24","author":"Aslanova","year":"2026","journal-title":"Clin Genitourin Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","author":"Galsky","year":"2025","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","article-title":"Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA","volume":"43","author":"Powles","year":"2025","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"S1140","DOI":"10.1016\/j.annonc.2024.08.2055","article-title":"1970MO circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial","volume":"35","author":"Drakaki","year":"2024","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/JCO.2024.42.4_suppl.534","article-title":"Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"42","author":"Young","year":"2024","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","volume":"29","author":"Van Dorp","year":"2023","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: Results from the TOMBOLA trial","author":"Dyrskjot","year":"2026","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1158\/1538-7445.Am2025-3770","article-title":"Abstract 3770: Comparison of ctDNA detection methods for monitoring minimal residual disease in patients with bladder cancer: Insights from the TOMBOLA trial","volume":"85","author":"Nordentoft","year":"2025","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03091-7","article-title":"Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial","volume":"30","author":"Powles","year":"2024","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/path.6166","article-title":"Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial","volume":"261","author":"Zang","year":"2023","journal-title":"J Pathol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13975","article-title":"Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma","volume":"26","author":"Hamada","year":"2023","journal-title":"Oncol Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31314","article-title":"Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA","volume":"124","author":"Agarwal","year":"2018","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2018.36.6_suppl.453","article-title":"Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC)","volume":"36","author":"McGregor","year":"2018","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32806","article-title":"Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and\/or cell-free DNA results","volume":"126","author":"Pal","year":"2020","journal-title":"Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.02.004","article-title":"Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: A pilot study","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01648-8","article-title":"Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma","volume":"126","author":"Shohdy","year":"2022","journal-title":"Br J Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0570","article-title":"Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk-prediction","volume":"29","author":"Salari","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1767712\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:28:09Z","timestamp":1775795289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1767712\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":69,"alternative-id":["10.3389\/fonc.2026.1767712"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1767712","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1767712"}}